• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amneal Pharmaceuticals upgraded by JP Morgan with a new price target

    9/6/24 7:29:08 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRX alert in real time by email
    JP Morgan upgraded Amneal Pharmaceuticals from Underweight to Neutral and set a new price target of $9.00
    Get the next $AMRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRX

    DatePrice TargetRatingAnalyst
    6/6/2025$12.00Buy
    Goldman
    2/24/2025$9.00 → $12.00Neutral → Overweight
    Analyst
    9/6/2024$9.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $AMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Amneal Pharmaceuticals with a new price target

      Goldman initiated coverage of Amneal Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      6/6/25 8:33:10 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Pharmaceuticals upgraded by Analyst with a new price target

      Analyst upgraded Amneal Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously

      2/24/25 7:02:03 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Pharmaceuticals upgraded by JP Morgan with a new price target

      JP Morgan upgraded Amneal Pharmaceuticals from Underweight to Neutral and set a new price target of $9.00

      9/6/24 7:29:08 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patel Gautam sold $761,146 worth of shares (94,906 units at $8.02), decreasing direct ownership by 6% to 1,609,144 units (SEC Form 4)

      4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

      6/18/25 4:11:43 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Patel Gautam sold $452,537 worth of shares (56,426 units at $8.02), decreasing direct ownership by 3% to 1,704,050 units (SEC Form 4)

      4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

      6/12/25 4:19:17 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Vice President Shah Nikita sold $372,481 worth of shares (49,140 units at $7.58), decreasing direct ownership by 11% to 388,929 units (SEC Form 4)

      4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

      5/19/25 4:16:23 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care